KR102030207B1 - 폴리하이드록시 크로메논 화합물의 합성 및 이의 항종양 효과 - Google Patents

폴리하이드록시 크로메논 화합물의 합성 및 이의 항종양 효과 Download PDF

Info

Publication number
KR102030207B1
KR102030207B1 KR1020147022558A KR20147022558A KR102030207B1 KR 102030207 B1 KR102030207 B1 KR 102030207B1 KR 1020147022558 A KR1020147022558 A KR 1020147022558A KR 20147022558 A KR20147022558 A KR 20147022558A KR 102030207 B1 KR102030207 B1 KR 102030207B1
Authority
KR
South Korea
Prior art keywords
cancer
compound
cells
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147022558A
Other languages
English (en)
Korean (ko)
Other versions
KR20140109498A (ko
Inventor
쿤 멩
홍시아 딩
진 리
Original Assignee
베이징 셰노젠 파마 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이징 셰노젠 파마 그룹 리미티드 filed Critical 베이징 셰노젠 파마 그룹 리미티드
Publication of KR20140109498A publication Critical patent/KR20140109498A/ko
Application granted granted Critical
Publication of KR102030207B1 publication Critical patent/KR102030207B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
KR1020147022558A 2012-01-13 2012-12-31 폴리하이드록시 크로메논 화합물의 합성 및 이의 항종양 효과 Expired - Fee Related KR102030207B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201210011031 2012-01-13
CN201210011031.8 2012-01-13
CN201210573072.6 2012-12-25
CN201210573072.6A CN103204838B (zh) 2012-01-13 2012-12-25 多羟基苯并吡喃酮类化合物的合成及其抗肿瘤作用
PCT/CN2012/088016 WO2013104263A1 (zh) 2012-01-13 2012-12-31 多羟基苯并吡喃酮类化合物的合成及其抗肿瘤作用

Publications (2)

Publication Number Publication Date
KR20140109498A KR20140109498A (ko) 2014-09-15
KR102030207B1 true KR102030207B1 (ko) 2019-10-08

Family

ID=48752268

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147022558A Expired - Fee Related KR102030207B1 (ko) 2012-01-13 2012-12-31 폴리하이드록시 크로메논 화합물의 합성 및 이의 항종양 효과

Country Status (11)

Country Link
US (1) US9221781B2 (enExample)
EP (1) EP2803665B1 (enExample)
JP (1) JP6113751B2 (enExample)
KR (1) KR102030207B1 (enExample)
CN (1) CN103204838B (enExample)
AU (1) AU2012365712B2 (enExample)
BR (1) BR112014016635B8 (enExample)
CA (1) CA2860999C (enExample)
ES (1) ES2627316T3 (enExample)
MX (1) MX364833B (enExample)
WO (1) WO2013104263A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101784990B1 (ko) * 2016-01-13 2017-10-12 주식회사 파이브지티 얼굴인식을 이용한 홈 오토메이션 제어 시스템 및 그 방법
CN107216303B (zh) * 2016-07-15 2020-04-21 北京盛诺基医药科技股份有限公司 氟可拉定的合成方法
CN107298667B (zh) * 2016-07-15 2020-09-08 北京盛诺基医药科技股份有限公司 淫羊藿素的合成方法
WO2018035246A1 (en) * 2016-08-16 2018-02-22 Uwm Research Foundation, Inc. Gaba(a) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma
US10266510B2 (en) 2017-01-18 2019-04-23 King Abdulaziz University Antimicrobial and cytotoxic compounds and methods for treating cancer, a bacterial infection, and/or a fungal infection
CN108947949B (zh) * 2017-05-19 2022-08-19 泰州华元医药科技有限公司 抗焦虑氘代化合物及其医药用途
CN109020938A (zh) * 2018-08-17 2018-12-18 昆明龙津药业股份有限公司 一种杨梅素的制备方法
CN110092770A (zh) * 2019-05-31 2019-08-06 北京盛诺基医药科技有限公司 一种黄酮化合物中间体的制备方法
CN110054605A (zh) * 2019-05-31 2019-07-26 北京盛诺基医药科技有限公司 一种淫羊藿素中间体的制备方法
CN112569222A (zh) * 2020-12-31 2021-03-30 赣南医学院 三氟淫羊藿素在制备改善疼痛、肿胀及运动功能的药物中的应用
CN112851615B (zh) * 2021-01-21 2023-04-07 厦门大学 一种异戊烯基黄酮的制备及其作为治疗宫颈癌药物的应用
CN113717138B (zh) * 2021-10-21 2023-02-24 沈阳药科大学 一类氮芥类色原酮衍生物与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101104611A (zh) * 2007-04-29 2008-01-16 殷正丰 一种3-甲氧基黄酮类化合物,其制备方法和应用
US20100016352A1 (en) * 2008-04-18 2010-01-21 Jin Li Compounds and methods for treating estrogen receptor-related diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1786864A (zh) 2004-12-10 2006-06-14 上海迪比特实业有限公司 一种计算机安全认证方法
JP2007332695A (ja) 2006-06-16 2007-12-27 Advanced Media Inc 電子錠装置及び音声認証ロッカーシステム
WO2008100977A2 (en) * 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
CN102038673B (zh) * 2009-10-20 2012-07-25 北京珅奥基医药科技有限公司 羟基苯并吡喃酮类化合物在制备治疗白血病药物中的应用
CN102558164B (zh) 2010-12-31 2016-06-15 北京盛诺基医药科技有限公司 苯并吡喃酮类雌激素受体调节剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101104611A (zh) * 2007-04-29 2008-01-16 殷正丰 一种3-甲氧基黄酮类化合物,其制备方法和应用
US20100016352A1 (en) * 2008-04-18 2010-01-21 Jin Li Compounds and methods for treating estrogen receptor-related diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bioorganic and Medicinal Chemistry Letters 11(1):75-77(2001.)*
Liebigs Annalen/Recueil 10:2169-2175(1997.)*
Molecular Pharmacology 16(2):556-568(1979.)*

Also Published As

Publication number Publication date
ES2627316T3 (es) 2017-07-27
CN103204838A (zh) 2013-07-17
EP2803665B1 (en) 2017-05-10
MX364833B (es) 2019-05-08
BR112014016635A8 (pt) 2017-07-04
JP6113751B2 (ja) 2017-04-12
CA2860999C (en) 2019-12-31
MX2014008526A (es) 2014-11-25
CA2860999A1 (en) 2013-07-18
JP2015503596A (ja) 2015-02-02
WO2013104263A1 (zh) 2013-07-18
EP2803665A4 (en) 2015-07-08
BR112014016635B1 (pt) 2021-07-13
AU2012365712B2 (en) 2017-04-20
US20150011618A1 (en) 2015-01-08
BR112014016635A2 (pt) 2017-06-13
AU2012365712A1 (en) 2014-07-24
BR112014016635B8 (pt) 2021-08-24
EP2803665A1 (en) 2014-11-19
CN103204838B (zh) 2017-06-09
KR20140109498A (ko) 2014-09-15
US9221781B2 (en) 2015-12-29

Similar Documents

Publication Publication Date Title
KR102030207B1 (ko) 폴리하이드록시 크로메논 화합물의 합성 및 이의 항종양 효과
US9090583B2 (en) Benzopyrone estrogen receptor regulator
CN102018698B (zh) 治疗雌激素受体相关疾病的化合物及其方法
CN106660974B (zh) 含氨磺酰基的1,2,5-噁二唑类衍生物、其制备方法及其在医药上的应用
US10398689B2 (en) Benzopiperidine derivative, preparation method thereof and medical use thereof
TW202321263A (zh) 磺醯胺衍生物、其製備方法及其在醫藥上的應用
CN114728905A (zh) 治疗性化合物及使用方法
CN115677662A (zh) 吲唑类化合物、其制备方法及其在医药上的应用
WO2022020605A1 (en) Treatment of metastasized estrogen receptor positive breast cancer
HK1187607B (en) Synthesis of polyhydroxy benzopyran ketone compound and anti-tumor effect thereof
HK1187607A (en) Synthesis of polyhydroxy benzopyran ketone compound and anti-tumor effect thereof
JP2022504760A (ja) 化学療法難治性がんの治療のための新しい併用薬方法
HK1172907A (en) Benzopyrone estrogen receptor (er) modulator
CN103965172A (zh) 治疗雌激素受体相关疾病的化合物及其方法
CN101941959B (zh) 二羟基苯并吡喃酮类化合物在制备预防和治疗骨折和骨质疏松的药物中的应用
KR101634758B1 (ko) 에스트로겐 수용체 리간드로서의 2-하이드록시-7-메틸 옥타하이드로페난트렌 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 약학 조성물
WO2024099435A1 (zh) Tead抑制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20231002

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20231002